

Table 1 PLGG with KIAA1549-BRAF fusion: patient characteristics, response, and toxicity with trametinib

<table><tr><td/><td>Cases Age at diagnosis (years); sex</td><td>Histologic diagnosis; tumor location</td><td>Prior surgery</td><td>Prior therapy</td><td>Age on treatment onset (years)</td><td>Time on treatment (months)</td><td>Best overall response</td><td>Functional response</td><td>Side effects</td></tr><tr><td>Case 1</td><td>1.5; \( \mathrm{F} \)</td><td>PA; medulla oblongata with leptomeningeal dissemination</td><td>Biopsy</td><td>CPT 11-CDDP; VBL</td><td>5.8</td><td>20</td><td>PR</td><td>Stable</td><td>Skin (grade II) Abdominal pain (grade II) Cheilitis (grade I) CPK and AP increased (grade I)</td></tr><tr><td>Case 2</td><td>0.5 ; \( \mathrm{M} \)</td><td>PMA; hypothalamic- chiasmatic</td><td>Biopsy, PR</td><td>VCR-CBCDA; 5 DR-BEV</td><td>1</td><td>18</td><td>SD</td><td>Stable</td><td>Skin (grade I) Cheilitis (grade I)</td></tr><tr><td>Case 3</td><td>0.9 ; \( \mathrm{F} \)</td><td>PA; intramedullary</td><td>Biopsy</td><td>VCR-CBCDA; CPT 11-CDDP</td><td>12</td><td>15</td><td>SD</td><td>Improvement of brachial hemiparesis, resolution of paresthesia in hands and torticollis</td><td>Skin (grade II) Alopecia (grade I) Vasculitis (grade III) CPK and ALT increased (grade I)</td></tr><tr><td>Case 4</td><td>1; \( \mathrm{M} \)</td><td>PMA; hypothalamic- chiasmatic</td><td>Biopsy</td><td>CPT 11-CDDP; VBL; BEV-CDDP; BEV</td><td>7.5</td><td>5</td><td>SD</td><td>Stable</td><td>Skin (grade II) Cheilitis (grade I) Mucositis oral (grade I) Abdominal pain (grade I) Fatigue and anorexia (grade II) CPK increased (grade I)</td></tr><tr><td>Case 5</td><td>4.4; \( \mathrm{F} \)</td><td>PA; hypothalamic- chiasmatic</td><td>Biopsy, PR</td><td>CPT 11-CDDP; VBL; BEV-CDDP</td><td>12.5</td><td>8</td><td>PD</td><td>Visual deterioration</td><td>Skin (grade II) Alopecia (grade II) Cheilitis (grade III) Mucositis oral (grade II) Fatigue and anorexia (grade II)</td></tr><tr><td>Case 6</td><td>5.8; F</td><td>PA; intramedullary</td><td>Biopsy, PR</td><td>CPT 11-CDDP; VBL; BEV-CDDP</td><td>12.3</td><td>15</td><td>SD</td><td>Resolution of paresthesia in hands</td><td>Skin (grade I) Alopecia (grade I) Mucositis oral (grade I) CPK and LDH increased (grade I)</td></tr><tr><td>Case 7</td><td>0.8 ; F</td><td>PMA; hypothalamic- chiasmatic</td><td>Biopsy</td><td>VCR-CBCDA; BEV</td><td>2.8</td><td>6</td><td>PD</td><td>Stable</td><td>Skin (grade II) Alopecia (grade I) Abdominal pain (grade I)</td></tr><tr><td>Case 8</td><td>1.8; \( \mathrm{M} \)</td><td>PAs; hypothalamic- chiasmatic</td><td>Biopsy</td><td>VCR-CBCDA; VBL</td><td>2.9</td><td>6</td><td>PD</td><td>Increased hemiparesis and cranial nerve abnormalities</td><td>Skin (grade I)</td></tr><tr><td>Case 9</td><td>3.9; \( \mathrm{M} \)</td><td>PA; hypothalamic- chiasmatic with leptomeningeal dissemination</td><td>PR</td><td>CPT 11-CDDP</td><td>9.6</td><td>14 (continue)</td><td>SD</td><td>Stable</td><td>Skin (grade II) Abdominal pain (grade I) CPK increased (grade II) AST and LDH increased (grade I)</td></tr><tr><td>Case 10</td><td>0.4 ; \( \mathrm{M} \)</td><td>PMA; hypothalamic- chiasmatic</td><td>Biopsy PR</td><td>VCR-CBCDA; VBL-BEV 1.8</td><td/><td>14 (continue)</td><td>SD</td><td>Diencephalic syndrome improvement</td><td>Skin (grade II) Abdominal pain (grade II) Vomiting (grade I) CPK increased (grade II)</td></tr><tr><td>Case 11</td><td>1.1; \( \mathrm{F} \)</td><td>GG; intramedullary</td><td>Biopsy, PR</td><td>CPT 11-CDDP: VBL: VCR-CBCDA; BEV-CPT 11</td><td>10.8</td><td>12 (continue)</td><td>SD</td><td>Stable</td><td>Skin (grade I) Cystitis (grade II) Lymph gland infection (grade III) LDH increased (grade I)</td></tr></table>

